The atropine landscape is constantly evolving as new studies are published. Here is a compiled summary of all of the most recent atropine eye drop studies for myopia control, along with information on trials currently underway.
Welcome to Part 2 of the updates from the American Academy of Optometry 2019 Meeting. These updates all sprung from Mark Bullimore and Noel Brennan’s fantastic session entitled Twelve Evidence Based Things That We Should Know About Myopia.
AAO2019 Meeting and third biannual World Congress of Optometry– Addressing the global myopia burden: guest summary by Sally Dillehay.
Whilst each individual child has their own circumstances and situation to consider when prescribing myopia control, children with astigmatism present a unique set of challenges when selecting the best option for not only slowing down the progression of their axial growth, but also providing them with good vision.
Welcome to Part 2 of the ARVO 2019 Research Roundup! For article abstracts and more info, please click on the headings.
Podcast summary: Professor Mark Bullimore of the University of Houston, Texas USA, tells us more on the complex topic of
Podcast summary: Professor James Loughman from Technological University Dublin, and the Centre for Eye Research Ireland, challenges us to think
This article groups common clinical treatments in an effort to explore what we do and don’t know regarding myopia control efficacy. It highlights the need to balance the available evidence with emerging knowledge when discussing options for myopia control with patients and their carers.
Three more fascinating areas and/or pieces of research presented at IMC, and some bonus material.
Atropine for the treatment of childhood myopia has in recent times been more extensively researched through the ATOM trials with the latest update released on August 11,2015. The first paper in a series of three so far was published in 2006.
